Lyell Wealth Management LP decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.7% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 4,491 shares of the company’s stock after selling 484 shares during the period. Lyell Wealth Management LP’s holdings in Eli Lilly and Company were worth $378,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Joel Isaacson & Co. LLC boosted its position in shares of Eli Lilly and Company by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Eli Lilly and Company by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock worth $27,280,000 after buying an additional 9,680 shares in the last quarter. Franklin Street Advisors Inc. NC purchased a new position in shares of Eli Lilly and Company during the first quarter worth approximately $320,000. Washington Trust Bank boosted its position in shares of Eli Lilly and Company by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock worth $872,000 after buying an additional 4,990 shares in the last quarter. Finally, Independent Advisor Alliance purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $1,547,000. 75.49% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company (NYSE:LLY) opened at 82.29 on Monday. The firm has a 50-day moving average price of $80.49 and a 200-day moving average price of $79.95. The company has a market capitalization of $86.92 billion, a price-to-earnings ratio of 39.79 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72.
Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.02. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. The business had revenue of $5.23 billion for the quarter, compared to the consensus estimate of $5.22 billion. During the same period in the previous year, the business earned $0.83 earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post $4.12 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Eli Lilly and Company’s payout ratio is 100.48%.
A number of research analysts have recently commented on LLY shares. BMO Capital Markets set a $71.00 price target on Eli Lilly and Company and gave the company a “sell” rating in a research report on Tuesday, April 25th. Credit Suisse Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 21st. Barclays PLC upped their price target on Eli Lilly and Company from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, April 7th. Zacks Investment Research cut Eli Lilly and Company from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $92.00 price target (down previously from $94.00) on shares of Eli Lilly and Company in a research report on Saturday, April 29th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $87.65.
In other news, SVP Enrique A. Conterno sold 25,000 shares of the business’s stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $82.76, for a total value of $2,069,000.00. Following the transaction, the senior vice president now directly owns 114,217 shares in the company, valued at $9,452,598.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the transaction, the insider now owns 14,041 shares in the company, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders sold 474,733 shares of company stock worth $39,634,487 over the last 90 days. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Company Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284319/lyell-wealth-management-lp-lowers-stake-in-eli-lilly-and-company-nyselly.html
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.